Analysis of lectin binding to glycolipid complexes using combinatorial glycoarrays

Glycobiology

Volumn 19, Issue 7, 2009, Pages 789-796

  Rinaldi, Simon ^a   Brennan, Kathryn M ^a   Goodyear, Carl S ^a   O'Leary, Colin ^a   Schiavo, Giampietro ^b   Crocker, Paul R ^c   Willison, Hugh J ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^c UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Complexes; Ganglio side; Glycoarray; Glycolipid; Lectin

Indexed keywords

ANTIBODY; BACTERIAL TOXIN; GANGLIOSIDE; GLYCOLIPID; HETERODIMER; LECTIN; LIPOSOME; POLYVINYLIDENE FLUORIDE;

ARTICLE; BINDING AFFINITY; BINDING ASSAY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; INTERMETHOD COMPARISON; LECTIN BINDING; LIPID ANALYSIS; MICROBIAL ATTENUATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN CARBOHYDRATE INTERACTION; PROTEIN GLYCOSYLATION; PROTEIN LIPID INTERACTION; THIN LAYER CHROMATOGRAPHY;

ANTIBODIES; BACTERIAL TOXINS; BINDING SITES; CHROMATOGRAPHY, THIN LAYER; GLYCOLIPIDS; LECTINS; MICROARRAY ANALYSIS; POLYSACCHARIDES;

BACTERIA (MICROORGANISMS);

EID: 66249126827     PISSN: 09596658     EISSN: 14602423     Source Type: Journal    
DOI: 10.1093/glycob/cwp049     Document Type: Article

References (37)

1. Avril T, North SJ, Haslam SM, Willison HJ, Crocker PR. 2006. Probing the cis interactions of the inhibitory receptor Siglec-7 with alpha2,8-disialylated ligands on natural killer cells and other leukocytes using glycan-specific antibodies and by analysis of alpha2,8-sialyltransferase gene expression. J Leukoc Biol. 80(4):787-796.
2. Avril T, Wagner ER, Willison HJ, Crocker PR. 2006. Sialic acid-binding immunoglobulin-like lectin 7 mediates selective recognition of sialylated glycans expressed on Campylobacter jejuni lipooligosaccharides. Infect Immun. 74(7):4133-4141.
3. Blixt O, Head S, Mondala T, Scanlan C, Huflejt ME, Alvarez R, Bryan MC, Fazio F, Calarese D, Stevens J, et al. 2004. Printed covalent glycan array for ligand profiling of diverse glycan binding proteins. Proc Natl Acad Sci USA. 101(49):17033-17038.
4. Boffey J, Nicholl D, Wagner ER, Townson K, Goodyear C, Furukawa K, Furukawa K, Conner J, Willison HJ. 2004. Innate murine B cells produce anti-disialosyl antibodies reactive with Campylobacter jejuni LPS and gangliosides that are polyreactive and encoded by a restricted set of unmutated V genes. J Neuroimmunol. 152(1-2):98-111.
5. Boffey J, Odaka M, Nicoll D, Wagner ER, Townson K, Bowes T, Conner J, Furukawa K, Willison HJ. 2005. Characterisation of the immunoglobulin variable region gene usage encoding the murine anti-ganglioside antibody repertoire. J Neuroimmunol. 165(1-2):92-103.
6. Bowes T, Wagner ER, Boffey J, Nicholl D, Cochrane L, Benboubetra M, Conner J, Furukawa K, Furukawa K, Willison HJ. 2002. Tolerance to self gangliosides is the major factor restricting the antibody response to lipopolysaccharide core oligosaccharides in Campylobacter jejuni strains associated with Guillain-Barre syndrome. Infect Immun. 70(9):5008-5018.
7. Byres E, Paton AW, Paton JC, Lofling JC, Smith DF, Wilce MC, Talbot UM, Chong DC, Yu H, Huang S, et al. 2008. Incorporation of a non-human glycan mediates human susceptibility to a bacterial toxin. Nature. 456(7222):648-652.
8. Chabraoui F, Derrington EA,Mallie-Didier F, Confavreux C, Quincy C, Caudie C. 1993. Dot-blot immunodetection of antibodies against GM1 and other gangliosides on PVDF-P membranes. J Immunol Methods. 165(2):225-230.
9. Crocker PR, Paulson JC, Varki A. 2007. Siglecs and their roles in the immune system. Nat Rev Immunol. 7(4):255-266.
10. Crocker PR, Redelinghuys P. 2008. Siglecs as positive and negative regulators of the immune system. Biochem Soc Trans. 36(Pt 6):1467-1471.
11. Deinhardt K, Berninghausen O, Willison HJ, Hopkins CR, Schiavo G. 2006. Tetanus toxin is internalized by a sequential clathrin-dependent mechanism initiated within lipid microdomains and independent of epsin1. J Cell Biol. 174(3):459-471.
12. DeMarco ML, Woods RJ. 2008. Structural glycobiology: A game of snakes and ladders. Glycobiology. 18(6):426-440.
13. Goodyear CS, O'Hanlon GM, Plomp JJ, Wagner ER, Morrison I, Veitch J, Cochrane L, Bullens RW, Molenaar PC, Conner J, et al. 1999. Monoclonal antibodies raised against Guillain-Barre syndrome-associated Campylobacter jejuni lipopolysaccharides react with neuronal gangliosides and paralyze muscle-nerve preparations. J Clin Invest 104(6):697-708.
14. Greenshields KN, Halstead SK, Zitman FM, Rinaldi S, Brennan KM, O'Leary C, Chamberlain LH, Easton A, Roxburgh J, Pediani J, et al. 2009. The neuropathic potential of anti-GM1 autoantibodies is regulated by the local glycolipid environment. J Clin Invest. 119(3):595-610.
15. Hakomori SI. 2002. Inaugural article: The glycosynapse. Proc Natl Acad Sci USA. 99(1):225-232.
16. Kaida K, Kanzaki M, Morita D, Kamakura K, Motoyoshi K, Hirakawa M, Kusunoki S. 2006. Anti-ganglioside complex antibodies in Miller Fisher syndrome. J Neurol Neurosurg Psychiatry. 77(9):1043-1046.
17. Kaida K, Morita D, Kanzaki M, Kamakura K, Motoyoshi K, Hirakawa M, Kusunoki S. 2004. Ganglioside complexes as new target antigens in Guillain-Barre syndrome. Ann Neurol. 56(4):567-571.
18. Kaida K, Morita D, Kanzaki M, Kamakura K, Motoyoshi K, Hirakawa M, Kusunoki S. 2007. Anti-ganglioside complex antibodies associated with severe disability in GBS. J Neuroimmunol. 182(1-2):212-218.
19. Kanter JL, Narayana S, Ho PP, Catz I, Warren KG, Sobel RA, Steinman L, Robinson WH. 2006. Lipid microarrays identify key mediators of autoimmune brain inflammation. Nat Med. 12(1):138-143.
20. Karlsson KA. 2001. Pathogen-host protein-carbohydrate interactions as the basis of important infections. Adv Exp Med Biol. 491:431-443.
21. Kuijf ML, Van Doorn PA, Tio-Gillen AP, Geleijns K, Ang CW, Hooijkaas H, Hop WCJ, Jacobs BC. 2005. Diagnostic value of anti-GM1 ganglioside serology and validation of the INCAT-ELISA. J Neurol Sci. 239(1):37-44.
22. Kusunoki S, Kaida K, Ueda M. 2008. Antibodies against gangliosides and ganglioside complexes in Guillain-Barre syndrome: New aspects of research. Biochim Biophys Acta. 1780(3):441-444.
23. Lalli G, Bohnert S, Deinhardt K, Verastegui C, Schiavo G. 2003. The journey of tetanus and botulinum neurotoxins in neurons. Trends Microbiol. 11(9):431-437.
24. Lencer WI. 2004. Retrograde transport of cholera toxin into the ER of host cells. Int J Med Microbiol. 293(7-8):491-494.
25. Lencer WI, Hirst TR, Holmes RK. 1999. Membrane traffic and the cellular uptake of cholera toxin. Biochim Biophys Acta. 1450(3):177-190.
26. Miller-Podraza H, Johansson P, Angstrom J, Larsson T, Longard M, Karlsson KA. 2004. Studies on gangliosides with affinity for Helicobacter pylori: Binding to natural and chemically modified structures. Glycobiology. 14(3):205-217.
27. Paulson JC, Blixt O, Collins BE. 2006. Sweet spots in functional glycomics. Nat Chem Biol. 2(5):238-248.
28. Raman R, Raguram S, Venkataraman G, Paulson JC, Sasisekharan R. 2005. Glycomics: An integrated systems approach to structure-function relationships of glycans. Nat Methods. 2(11):817-824.
29. Rinaldi S, Willison HJ. 2008. Ganglioside antibodies and neuropathies. Curr Opin Neurol. 21(5):540-546.
30. Schiavo G, Van Der Goot FG. 2001. The bacterial toxin toolkit. Nat Rev Mol Cell Biol. 2(7):530-537.
31. Simons K, Ikonen E. 1997. Functional rafts in cell membranes. Nature 387(6633):569-572.
32. Todeschini AR, Dos Santos JN, Handa K, Hakomori SI. 2008. Ganglioside GM2/GM3 complex affixed on silica nanospheres strongly inhibits cell motility through CD82/cMet-mediated pathway. Proc Natl Acad Sci USA 105(6):1925-1930.
33. Todeschini AR, Hakomori SI. 2008. Functional role of glycosphingolipids and gangliosides in control of cell adhesion, motility, and growth, through glycosynaptic microdomains. Biochim Biophys Acta. 1780(3):421-433.
34. Townson K, Boffey J, Nicholl D, Veitch J, Bundle D, Zhang P, Samain E, Antoine T, Bernardi A, Arosio D, et al. 2007. Solid phase immunoadsorption for therapeutic and analytical studies on neuropathy-associated anti-GM1 antibodies. Glycobiology. 17(3):294-303.
35. Willison HJ. 2005. Ganglioside complexes: New autoantibody targets in Guillain-Barre syndromes. Nat Clin Pract Neurol. 1(1):2-3.
36. Willison HJ. 2006. Ganglioside complexes as targets for antibodies in Miller Fisher syndrome. J Neurol Neurosurg Psychiatry. 77(9):1002-1003.
37. Willison HJ, Veitch J, Swan AV, Baumann N, Comi G, Gregson NA, Illa I, Zielasek J, Hughes RA. 1999. Inter-laboratory validation of an ELISA for the determination of serum anti-ganglioside antibodies. Eur J Neurol 6(1):71-77.